MX2023008463A - Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras). - Google Patents

Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).

Info

Publication number
MX2023008463A
MX2023008463A MX2023008463A MX2023008463A MX2023008463A MX 2023008463 A MX2023008463 A MX 2023008463A MX 2023008463 A MX2023008463 A MX 2023008463A MX 2023008463 A MX2023008463 A MX 2023008463A MX 2023008463 A MX2023008463 A MX 2023008463A
Authority
MX
Mexico
Prior art keywords
methods
compositions
ras
inhibition
kras
Prior art date
Application number
MX2023008463A
Other languages
English (en)
Inventor
Rui Xu
Bin Wang
Yue Yang
Zuhui Zhang
Eli Wallace
Felice Lightstone
Paola Bisignano
Anna Elzbieta Maciag
David Michael Turner
Dhirendra Kumar Simanshu
Albert Hay Wah Chan
Christopher John Brassard
Tao Liao
Original Assignee
Leidos Biomedical Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leidos Biomedical Res Inc filed Critical Leidos Biomedical Res Inc
Publication of MX2023008463A publication Critical patent/MX2023008463A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Lubricants (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan compuestos de fórmula (I) y (II), o sales, ésteres, tautómeros, profármacos, formas zwitteriónicas o estereoisómeros de los mismos, así como composiciones farmacéuticas que los comprenden. También se proporcionan en este documento métodos para usar los mismos en la modulación (p. ej., inhibición) de KRAS (p. ej., KRAS que tiene una mutación G12D) y el tratamiento de enfermedades o trastornos, tal como cáncer, en sujetos que lo necesitan.
MX2023008463A 2021-02-16 2022-02-15 Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras). MX2023008463A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150011P 2021-02-16 2021-02-16
US202163246181P 2021-09-20 2021-09-20
PCT/US2022/016487 WO2022177917A2 (en) 2021-02-16 2022-02-15 Compositions and methods for inhibition of ras

Publications (1)

Publication Number Publication Date
MX2023008463A true MX2023008463A (es) 2023-12-07

Family

ID=80685119

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008463A MX2023008463A (es) 2021-02-16 2022-02-15 Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).

Country Status (11)

Country Link
US (1) US20240246954A1 (es)
EP (1) EP4294799A2 (es)
JP (1) JP2024508755A (es)
KR (1) KR20240002245A (es)
AU (1) AU2022224511A1 (es)
BR (1) BR112023016299A2 (es)
CA (1) CA3209083A1 (es)
IL (1) IL304986A (es)
MX (1) MX2023008463A (es)
TW (1) TW202245779A (es)
WO (1) WO2022177917A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12065430B2 (en) 2018-10-26 2024-08-20 Taiho Pharmaceutical Co., Ltd. Indazole compound or salt thereof
WO2023039240A1 (en) * 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
WO2023103523A1 (zh) * 2021-12-09 2023-06-15 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023133181A1 (en) * 2022-01-06 2023-07-13 Theras, Inc. Kras inhibitors
AR128211A1 (es) * 2022-01-06 2024-04-10 Theras Inc Composiciones y métodos para la inhibición de ras
TWI841200B (zh) * 2022-01-21 2024-05-01 大陸商上海湃隆生物科技有限公司 雜環類化合物、藥物組成物及其應用
WO2023154766A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023159086A1 (en) * 2022-02-16 2023-08-24 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
CN118715215A (zh) * 2022-02-16 2024-09-27 美国安进公司 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
WO2023179703A1 (en) * 2022-03-24 2023-09-28 Beigene , Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2023225252A1 (en) * 2022-05-20 2023-11-23 Theras, Inc. Compositions and methods for inhibition of ras
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024008179A1 (en) * 2022-07-07 2024-01-11 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024031088A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024030633A1 (en) * 2022-08-05 2024-02-08 Theras, Inc. Compositions and methods for inhibition of kras
WO2024030647A1 (en) 2022-08-05 2024-02-08 Theras, Inc. Compositions and methods for inhibition of ras
WO2024044667A2 (en) * 2022-08-26 2024-02-29 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2024063576A1 (ko) * 2022-09-23 2024-03-28 일동제약(주) Kras 저해 물질로서 신규한 퀴나졸린 화합물
WO2024083246A1 (en) * 2022-10-21 2024-04-25 Ascentage Pharma (Suzhou) Co., Ltd. Kras inhibitors
CN116554208A (zh) * 2022-12-02 2023-08-08 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
CN116082115A (zh) * 2023-01-06 2023-05-09 河南省科学院化学研究所有限公司 一种2-溴-4-氯-9,9’-二甲基芴的合成方法
US20240343736A1 (en) * 2023-03-30 2024-10-17 Eli Lilly And Company Kras inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) * 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
US9988357B2 (en) * 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) * 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
AU2019377130B2 (en) * 2018-11-09 2022-03-17 F. Hoffmann-La Roche Ag Fused ring compounds
CN112110918B (zh) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
EP4065231A1 (en) * 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4175947A4 (en) * 2020-06-30 2024-07-03 Inventisbio Co Ltd QUINAZOLINE COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
CN113880827B (zh) * 2020-07-03 2024-10-01 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
EP4223761A1 (en) * 2020-09-30 2023-08-09 Shanghai Pharmaceuticals Holding Co., Ltd. Quinazoline compound and application thereof

Also Published As

Publication number Publication date
WO2022177917A2 (en) 2022-08-25
AU2022224511A1 (en) 2023-08-10
US20240246954A1 (en) 2024-07-25
JP2024508755A (ja) 2024-02-28
WO2022177917A3 (en) 2022-09-22
EP4294799A2 (en) 2023-12-27
CA3209083A1 (en) 2022-08-25
BR112023016299A2 (pt) 2023-11-28
KR20240002245A (ko) 2024-01-04
IL304986A (en) 2023-10-01
TW202245779A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2023008463A (es) Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
WO2023004102A3 (en) Compositions and methods for inhibition of ras
MX2022006986A (es) Inhibidores de kras g12c.
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2024001824A (es) Compuestos heterociclicos y metodos de uso.
MX2019013574A (es) Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2023010411A (es) Inhibidores de erbb/btk.
EP3693369A3 (en) Bromodomain inhibitors
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
EA201200875A1 (ru) Ингибиторы сфингозинкиназы
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
MX2022004197A (es) Inhibidores del factor d del complemento para administracion oral.
ZA202304134B (en) A magl inhibitor
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.